case_images: PMC6260552_01
case_images: Significant neutrophilic engulfment in the cytoplasm of tumor cells with moderate pleomorphism (H.E., x200).
case_images: CRIONM2018-1301562.001.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.001.jpg
case_images: fig1
case_images: The internalized neutrophils were intact (Figure 1).
case_images: Irregular tumor infiltration to the salivary gland in the resected sample. Significant diffuse neutrophilic infiltration in the tumor cells and surrounding stroma (H.E., x100).
case_images: CRIONM2018-1301562.002.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.002.jpg
case_images: fig2
case_images: Some of the neutrophils in the tumor cells revealed degenerative changes by high-power field (x1000) microscopic evaluation (Figures 2-4), while some neutrophils included apoptotic bodies.
case_images: High-power field view of the marked area in Figure 2 (H.E., x400).
case_images: CRIONM2018-1301562.003.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.003.jpg
case_images: fig3
case_images: Some of the neutrophils in the tumor cells revealed degenerative changes by high-power field (x1000) microscopic evaluation (Figures 2-4), while some neutrophils included apoptotic bodies.
case_images: Neutrophil aggregates in the cytoplasm of the tumor cells. Degenerative manifestations were evident and noticeable in some neutrophils. Nucleus of the tumor cell (big arrow) and nucleus of the engulfed neutrophils (small arrows) (H.E., x1000).
case_images: CRIONM2018-1301562.004.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.004.jpg
case_images: fig4
case_images: Some of the neutrophils in the tumor cells revealed degenerative changes by high-power field (x1000) microscopic evaluation (Figures 2-4), while some neutrophils included apoptotic bodies.
case_images: Significant neutrophilic infiltration into the tumor cells and the background in the lymph node aspiration biopsy (PAP, x400).
case_images: CRIONM2018-1301562.005.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.005.jpg
case_images: fig5
case_images: Tumor recurrence occurred in the periparotid and right neck lymph nodes after six months (Figure 5).
case_images: MR image of the solid tumor before pembrolizumab treatment.
case_images: CRIONM2018-1301562.006.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.006.jpg
case_images: fig6
case_images: Following unresponsive chemotherapy, pembrolizumab treatment was started eight months prior to this study (Figure 6).
case_images: CT image of the rapidly growing tumor when the treatment was first interrupted.
case_images: CRIONM2018-1301562.007.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.007.jpg
case_images: fig7
case_images: Pembrolizumab was interrupted and antituberculous treatment was started. Pembrolizumab was commenced when the tumor progressed to a 15 cm mass (Figure 7).
case_images: MR image of the tumor following pembrolizumab treatment: decreased tumor size revealing remission.
case_images: CRIONM2018-1301562.008.jpg
case_images: PMC6260552_01_CRIONM2018-1301562.008.jpg
case_images: fig8
case_images: Following the fourth dose of pembrolizumab, the tumor regressed to 4 cm (Figure 8) and the patient is currently alive for four years.